Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 6, 2014, Pages 644-652

  Pinto, N ^a   Gamazon, E R ^a   Antao, N ^a   Myers, J ^a   Stark, A L ^a   Konkashbaev, A ^a   Im, H K ^a   Diskin, S J ^b   London, W B ^c,d   Ludeman, S M ^e   Maris, J M ^b   Cox, N J ^a   Cohn, S L ^a   Dolan, M E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c HARVARD UNIVERSITY   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PERFOSFAMIDE; PHOSPHORAMIDE MUSTARD; SMALL INTERFERING RNA;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IKZF3 GENE; IN VITRO STUDY; INTRON; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHILD; COHORT STUDIES; CYCLOHEXYLAMINES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NEUROBLASTOMA; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; QUALITY CONTROL; REAL-TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, SMALL INTERFERING; TREATMENT FAILURE;

EID: 84901234592     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.37     Document Type: Article

References (47)

1. Maris, J.M., Hogarty, M.D., Bagatell, R. & Cohn, S.L. Neuroblastoma. Lancet 369, 2106-2120 (2007
2. Cohn, S.L. et al.; INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J. Clin. Oncol. 27, 289-297 (2009
3. Matthay, K.K. et al. Long-Term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study. J. Clin. Oncol. 27, 1007-1013 (2009
4. Berthold, F. et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol. 6, 649-658 (2005
5. Yu, A.L. et al.; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324-1334 (2010
6. Pinto, N., Cohn, S.L. & Dolan, M.E. Using germline genomics to individualize pediatric cancer treatments. Clin. Cancer Res. 18, 2791-2800 (2012
7. O'Donnell, P.H. & Ratain, M.J. Germline pharmacogenomics in oncology: Decoding the patient for targeting therapy. Mol. Oncol. 6, 251-259 (2012
8. Gonzalez-Angulo, A.M., Hennessy, B.T. & Mills, G.B. Future of personalized medicine in oncology: A systems biology approach. J. Clin. Oncol. 28, 2777-2783 (2010
9. Zhang, W., Huang, R.S. & Dolan, M.E. Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. Trends Cancer Res. 4, 1-13 (2008
10. Welsh, M. et al. Pharmacogenomic discovery using cell-based models. Pharmacol. Rev. 61, 413-429 (2009
11. Cox, N.J., Gamazon, E.R., Wheeler, H.E. & Dolan, M.E. Clinical translation of cell-based pharmacogenomic discovery. Clin. Pharmacol. Ther. 92, 425-427 (2012
12. The International HapMap Consortium. The International HapMap Project. Nature 426, 789-796 (2003
13. Wheeler, H.E. et al.; Cancer and Leukemia Group B. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin. Cancer Res. 19, 491-499 (2013
14. Ziliak, D. et al. Germline polymorphisms discovered via a cell-based, genomewide approach predict platinum response in head and neck cancers. Transl. Res. 157, 265-272 (2011
15. Huang, R.S. et al.; Australian Ovarian Cancer Study Group. Platinum sensitivityrelated germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin. Cancer Res. 17, 5490-5500 (2011
16. Gamazon, E.R. et al. Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. J. Natl. Cancer Inst. 105, 302-309 (2013
17. Gamazon, E.R., Huang, R.S., Cox, N.J. & Dolan, M.E. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc. Natl. Acad. Sci. USA 107, 9287-9292 (2010
18. Gamazon, E.R. et al. SCAN: SNP and copy number annotation. Bioinformatics 26, 259-262 (2010
19. Ernst, J. & Kellis, M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat. Biotechnol. 28, 817-825 (2010
20. Ludeman, S.M. The chemistry of the metabolites of cyclophosphamide. Curr. Pharm. Des. 5, 627-643 (1999
21. Cox, P.J. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochem. Pharmacol. 28, 2045-2049 (1979
22. Fleming, R.A. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17, 146S-154S (1997
23. Ekhart, C., Doodeman, V.D., Rodenhuis, S., Smits, P.H., Beijnen, J.H. & Huitema, A.D. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet. Genomics 18, 515-523 (2008
24. Bown, N. et al.; U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. Med. Pediatr. Oncol. 36, 14-19 (2001
25. Morgan, B. et al. Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. EMBO J. 16, 2004-2013 (1997
26. Oyadomari, S. & Mori, M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 11, 381-389 (2004
27. Cantero-Recasens, G., Fandos, C., Rubio-Moscardo, F., Valverde, M.A. & Vicente, R. The asthma-Associated ORMDL3 gene product regulates endoplasmic reticulum-mediated calcium signaling and cellular stress. Hum. Mol. Genet. 19, 111-121 (2010
28. Balasubramanian, M.N., Butterworth, E.A. & Kilberg, M.S. Asparagine synthetase: Regulation by cell stress and involvement in tumor biology. Am. J. Physiol. Endocrinol. Metab. 304, E789-E799 (2013
29. Schleicher, S.M., Moretti, L., Varki, V. & Lu, B. Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer: Implications for future therapeutic approaches. Drug Resist. Updat. 13, 79-86 (2010
30. Rossi, M., Sayan, A.E., Terrinoni, A., Melino, G. & Knight, R.A. Mechanism of induction of apoptosis by p73 and its relevance to neuroblastoma biology. Ann. NY Acad. Sci. 1028, 143-149 (2004
31. Spitz, M.R., Wu, X. & Mills, G. Integrative epidemiology: From risk assessment to outcome prediction. J. Clin. Oncol. 23, 267-275 (2005
32. Lessard, C.J. et al.; BIOLUPUS Network; GENLES Network. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am. J. Hum. Genet. 90, 648-660 (2012
33. Strachan, D.P. et al. Lifecourse influences on health among British adults: Effects of region of residence in childhood and adulthood. Int. J. Epidemiol. 36, 522-531 (2007
34. Hakomori, S. Glycosylation defining cancer malignancy: New wine in an old bottle. Proc. Natl. Acad. Sci. USA 99, 10231-10233 (2002
35. Long, P.M., Stradecki, H.M., Minturn, J.E., Wesley, U.V. & Jaworski, D.M. Differential aminoacylase expression in neuroblastoma. Int. J. Cancer 129, 1322-1330 (2011
36. Zon, G. et al. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis-And trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways. J. Med. Chem. 27, 466-485 (1984
37. Flowers, J.L. et al. Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide. Cancer Chemother. Pharmacol. 45, 335-344 (2000
38. Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A. & Reich, D. Principal components analysis corrects for stratification in genomewide association studies. Nat. Genet. 38, 904-909 (2006
39. Henderson, T.O. et al. Racial and ethnic disparities in risk and survival in children with neuroblastoma: A Children's Oncology Group study. J. Clin. Oncol. 29, 76-82 (2011
40. Maris, J.M. et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N. Engl. J. Med. 358, 2585-2593 (2008
41. Capasso, M. et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat. Genet. 41, 718-723 (2009
42. Wang, K. et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 469, 216-220 (2011
43. Diskin, S.J. et al. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat. Genet. 44, 1126-1130 (2012
44. Shterev, I.D., Jung, S.H., George, S.L. & Owzar, K. permGPU: Using graphics processing units in RNA microarray association studies. BMC Bioinformatics 11, 329 (2010
45. Huang, R.S. et al. Identification of genetic variants contributing to cisplatininduced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet. 81, 427-437 (2007
46. R Development Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/; (2010
47. Bates, D., Maechler, M., & Bolker, B. lme4: Linear mixed-effects models using S4 classes. R package version 0.999999-0. http://CRAN.R-project. org/package=lme4 (2012